Genome-Wide Association Studies of Drug-Resistance Determinants

Trends in Parasitology

Volumn 33, Issue 3, 2017, Pages 214-230

  Volkman, Sarah K ^a,b,c   Herman, Jonathan ^a,d   Lukens, Amanda K ^a,b   Hartl, Daniel L ^b,e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c SIMMONS COLLEGE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ANTIMALARIAL DRUG RESISTANCE; DRUG RESPONSE; GENE LOCUS; GENETIC LINKAGE; GENETIC SELECTION; GENETIC TRAIT; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HEREDITY; HUMAN; INHERITANCE; MALARIA; NONHUMAN; PHENOTYPE; PLASMODIUM FALCIPARUM; POPULATION GENETICS; REVIEW; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; PARASITOLOGY;

ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; GENETICS, POPULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALARIA; PLASMODIUM FALCIPARUM;

EID: 85006049209     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2016.10.001     Document Type: Review

References (135)

1. 1 WHO, World Malaria Report 2015. 2015, WHO, 280.
2. 2 Penman, B., et al. Genome-wide association studies in Plasmodium species. BMC Biol. 8 (2010), 90–92.
3. 3 Mwangi, J.M., Ranford-Cartwright, L.C., Genetic and genomic approaches for the discovery of parasite genes involved in antimalarial drug resistance. Parasitology 140 (2013), 1455–1467.
4. 4 Anderson, T., et al. How can we identify parasite genes that underlie antimalarial drug resistance?. Pharmacogenomics 12 (2011), 59–85.
5. 5 Anderson, T.J., Mapping drug resistance genes in Plasmodium falciparum by genome-wide association. Curr. Drug Targets Infect. Disord. 4 (2004), 65–78.
6. 6 Nair, S., et al. A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. Mol. Biol. Evol. 20 (2003), 1526–1536.
7. 7 Wootton, J.C., et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 418 (2002), 320–323.
8. 8 Fidock, D.A., et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6 (2000), 861–871.
9. 9 Wellems, T.E., et al. Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 3382–3386.
10. 10 Anderson, T.J., et al. Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology 119 (1999), 113–125.
11. 11 Su, X., et al. A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum. Science 286 (1999), 1351–1353.
12. 12 Foote, S.J., et al. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 345 (1990), 255–258.
13. 13 Wilson, C.M., et al. Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. Science 244 (1989), 1184–1186.
14. 14 Peterson, D.S., et al. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. U. S. A. 87 (1990), 3018–3022.
15. 15 Peterson, D.S., et al. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. U. S. A. 85 (1988), 9114–9118.
16. 16 Foote, S.J., et al. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. U. S. A. 87 (1990), 3014–3017.
17. 17 Triglia, T., et al. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 13944–13949.
18. 18 Djimde, A., et al. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344 (2001), 257–263.
19. 19 Gardner, M.J., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419 (2002), 498–511.
20. 20 Volkman, S.K., et al. A genome-wide map of diversity in Plasmodium falciparum. Nat. Genet. 39 (2007), 113–119.
21. 21 Jeffares, D.C., et al. Genome variation and evolution of the malaria parasite Plasmodium falciparum. Nat. Genet. 39 (2007), 120–125.
22. 22 Mu, J., et al. Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nat. Genet. 39 (2007), 126–130.
23. 23 Kidgell, C., et al. A systematic map of genetic variation in Plasmodium falciparum. PLoS Pathog., 2, 2006, e57.
24. 24 Neafsey, D.E., et al. Genome-wide SNP genotyping highlights the role of natural selection in Plasmodium falciparum population divergence. Genome Biol., 9, 2008, R171.
25. 25 Tan, J.C., et al. An optimized microarray platform for assaying genomic variation in Plasmodium falciparum field populations. Genome Biol., 12, 2011, R35.
26. 26 Van Tyne, D., et al. Identification and functional validation of the novel antimalarial resistance locus PF10_0355 in Plasmodium falciparum. PLoS Genet., 7, 2011, e101383.
27. 27 Mu, J., et al. Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat. Genet. 42 (2010), 268–271.
28. 28 Takala-Harrison, S., et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J. Infect. Dis. 211 (2015), 670–679.
29. 29 Dharia, N.V., et al. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol., 10, 2009, R21.
30. 30 Nair, S., et al. Adaptive copy number evolution in malaria parasites. PLoS Genet., 4, 2008, e1000243.
31. 31 Ioannidis, J.P.A., Why most published research findings are false. PLoS Med., 2, 2005, e124.
32. 32 Kraft, P., et al. Replication in genome-wide association studies. Stat. Sci. 24 (2009), 561–573.
33. 33 Nkhoma, S.C., et al. Population genetic correlates of declining transmission in a human pathogen. Mol. Ecol. 22 (2013), 273–285.
34. 34 Nkhoma, S.C., et al. Close kinship within multiple-genotype malaria parasite infections. Proc. Biol. Sci. 279 (2012), 2589–2598.
35. 35 Ariey, F., et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505 (2014), 50–55.
36. 36 Wendler, J.P., et al. A genome wide association study of Plasmodium falciparum susceptibility to 22 antimalarial drugs in Kenya. PLoS One, 9, 2014, e96486.
37. 37 Van Tyne, D., et al. Modulation of PF10_0355 (MSPDBL2) alters Plasmodium falciparum response to antimalarial drugs. Antimicrob. Agents Chemother. 57 (2013), 2937–2941.
38. 38 Park, D.J., et al. Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 13052–13057.
39. 39 Mok, S., et al. Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 347 (2015), 431–435.
40. 40 Dogovski, C., et al. Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance. PLoS Biol., 13, 2015, e1002132.
41. 41 White, N.J., Artemisinin resistance – the clock is ticking. Lancet 376 (2010), 2051–2052.
42. 42 Cheeseman, I.H., et al. A major genome region underlying artemisinin resistance in malaria. Science 336 (2012), 79–82.
43. 43 Miotto, O., et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat. Genet. 47 (2015), 226–234.
44. 44 Takala-Harrison, S., et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 240–245.
45. 45 Straimer, J., et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347 (2015), 428–431.
46. 46 Ghorbal, M., et al. Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system. Nat. Biotechnol. 32 (2014), 819–821.
47. 47 Yuan, J., et al. Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science 333 (2011), 724–729.
48. 48 Ferdig, M.T., Su, X.Z., Microsatellite markers and genetic mapping in Plasmodium falciparum. Parasitol. Today 16 (2000), 307–312.
49. 49 Wellems, T.E., Plowe, C.V., Chloroquine-resistant malaria. J. Infect. Dis. 184 (2001), 770–776.
50. 50 Preechapornkul, P., et al. Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness. Antimicrob. Agents Chemother. 53 (2009), 1509–1515.
51. 51 Cravo, P.V., et al. Genetics of mefloquine resistance in the rodent malaria parasite Plasmodium chabaudi. Antimicrob. Agents Chemother. 47 (2003), 709–718.
52. 52 Kublin, J.G., et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 185 (2002), 380–388.
53. 53 Hyde, J.E., et al. Plasmodium falciparum: a paradigm for alternative folate biosynthesis in diverse microorganisms?. Trends Parasitol. 24 (2008), 502–508.
54. 54 Chiodini, P.L., et al. Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. J. Antimicrob. Chemother. 36 (1995), 1073–1078.
55. 55 Fisher, N., et al. Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression. J. Biol. Chem. 287 (2012), 9731–9741.
56. 56 Korsinczky, M., et al. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemother. 44 (2000), 2100–2108.
57. 57 Wang, Z., et al. Artemisinin resistance at the China-Myanmar border and association with mutations in the K13 propeller gene. Antimicrob. Agents Chemother. 59 (2015), 6952–6959.
58. 58 Ferdig, M.T., et al. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol. Microbiol. 52 (2004), 985–997.
59. 59 Volkman, S.K., et al. Functional complementation of the ste6 gene of Saccharomyces cerevisiae with the pfmdr1 gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 8921–8925.
60. 60 Jiang, H., et al. Detection of genome-wide polymorphisms in the AT-rich Plasmodium falciparum genome using a high-density microarray. BMC Genomics, 9, 2008, 398.
61. 61 Ribacke, U., et al. Genome wide gene amplifications and deletions in Plasmodium falciparum. Mol. Biochem. Parasitol. 155 (2007), 33–44.
62. 62 Heinberg, A., Kirkman, L., The molecular basis of antifolate resistance in Plasmodium falciparum: looking beyond point mutations. Ann. N. Y. Acad. Sci. 1342 (2015), 10–18.
63. 63 Causton, H.C., et al. Remodeling of yeast genome expression in response to environmental changes. Mol. Biol. Cell 12 (2001), 323–337.
64. 64 Lambert, G., Kussell, E., Memory and fitness optimization of bacteria under fluctuating environments. PLoS Genet., 10, 2014, e1004556.
65. 65 Blake, W.J., et al. Noise in eukaryotic gene expression. Nature 422 (2003), 633–637.
66. 66 Karmodiya, K., et al. A comprehensive epigenome map of Plasmodium falciparum reveals unique mechanisms of transcriptional regulation and identifies H3K36me2 as a global mark of gene suppression. Epigenetics Chromatin, 8, 2015, 32.
67. 67 Ay, F., et al. Three-dimensional modeling of the P. falciparum genome during the erythrocytic cycle reveals a strong connection between genome architecture and gene expression. Genome Res. 24 (2014), 974–988.
68. 68 Gupta, A.P., et al. Dynamic epigenetic regulation of gene expression during the life cycle of malaria parasite Plasmodium falciparum. PLoS Pathog., 9, 2013, e1003170.
69. 69 Hoeijmakers, W.A., et al. H2A.Z/H2B.Z. double-variant nucleosomes inhabit the AT-rich promoter regions of the Plasmodium falciparum genome. Mol. Microbiol. 87 (2013), 1061–1073.
70. 70 Ponts, N., et al. Genome-wide mapping of DNA methylation in the human malaria parasite Plasmodium falciparum. Cell Host Microbe 14 (2013), 696–706.
71. 71 Broadbent, K.M., et al. A global transcriptional analysis of Plasmodium falciparum malaria reveals a novel family of telomere-associated lncRNAs. Genome Biol., 12, 2011, R56.
72. 72 Sierra-Miranda, M., et al. Two long non-coding RNAs generated from subtelomeric regions accumulate in a novel perinuclear compartment in Plasmodium falciparum. Mol. Biochem. Parasitol. 185 (2012), 36–47.
73. 73 Ukaegbu, U.E., Deitsch, K.W., The emerging role for RNA polymerase II in regulating virulence gene expression in malaria parasites. PLoS Pathog., 11, 2015, e1004926.
74. 74 Vembar, S.S., et al. Noncoding RNAs as emerging regulators of Plasmodium falciparum virulence gene expression. Curr. Opin. Microbiol. 20 (2014), 153–161.
75. 75 Lemieux, J.E., et al. Genome-wide profiling of chromosome interactions in Plasmodium falciparum characterizes nuclear architecture and reconfigurations associated with antigenic variation. Mol. Microbiol. 90 (2013), 519–537.
76. 76 Bopp, S.E., et al. Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families. PLoS Genet., 9, 2013, e1003293.
77. 77 Claessens, A., et al. Generation of antigenic diversity in Plasmodium falciparum by structured rearrangement of Var genes during mitosis. PLoS Genet., 10, 2014, e1004812.
78. 78 Vembar, S.S., et al. Complete telomere-to-telomere de novo assembly of the Plasmodium falciparum genome through long-read (>11 kb), single molecule, real-time sequencing. DNA Res. 23 (2016), 339–351.
79. 79 Ginsburg, H., et al. Characterization of permeation pathways appearing in the host membrane of Plasmodium falciparum infected red blood cells. Mol. Biochem. Parasitol. 14 (1985), 313–322.
80. 80 McCormick, G.J., Amino acid transport and incorporation in red blood cells of normal and Plasmodium knowlesi-infected rhesus monkeys. Exp. Parasitol. 27 (1970), 143–149.
81. 81 Nguitragool, W., et al. Malaria parasite clag3 genes determine channel-mediated nutrient uptake by infected red blood cells. Cell 145 (2011), 665–677.
82. 82 Comeaux, C.A., et al. Functional analysis of epigenetic regulation of tandem RhopH1/clag genes reveals a role in Plasmodium falciparum growth. Mol. Microbiol. 80 (2011), 378–390.
83. 83 Sharma, P., et al. An epigenetic antimalarial resistance mechanism involving parasite genes linked to nutrient uptake. J. Biol. Chem. 288 (2013), 19429–19440.
84. 84 Mira-Martinez, S., et al. Epigenetic switches in clag3 genes mediate blasticidin S resistance in malaria parasites. Cell. Microbiol. 15 (2013), 1913–1923.
85. 85 Herman, J.D., et al. A genomic and evolutionary approach reveals nongenetic drug resistance in malaria. Genome Biol., 15, 2014, 511.
86. 86 Herman, J.D., et al. The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. Sci. Transl. Med., 7, 2015, 288ra77.
87. 87 Jain, V., et al. Structural and functional analysis of the anti-malarial drug target prolyl-tRNA synthetase. J. Struct. Funct. Genomics 15 (2014), 181–190.
88. 88 Yona, A.H., et al. A relay race on the evolutionary adaptation spectrum. Cell 163 (2015), 549–559.
89. 89 Henikoff, S., Shilatifard, A., Histone modification: cause or cog?. Trends Genet. 27 (2011), 389–396.
90. 90 Deans, C., Maggert, K.A., What do you mean, “epigenetic”?. Genetics 199 (2015), 887–896.
91. 91 Holliday, R., Epigenetics: an overview. Dev. Genet. 15 (1994), 453–457.
92. 92 Amaratunga, C., et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect. Dis. 16 (2016), 357–365.
93. 93 Codd, A., et al. Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure. Malaria J., 10, 2011, 56.
94. 94 Hoshen, M.B., et al. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of ‘dormancy’, a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology 121:Pt 3 (2000), 237–246.
95. 95 Teuscher, F., et al. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J. Infect. Dis. 202 (2010), 1362–1368.
96. 96 Eastman, R.T., et al. Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob. Agents Chemother. 55 (2011), 3908–3916.
97. 97 Beghain, J., et al. Plasmodium copy number variation scan: gene copy numbers evaluation in haploid genomes. Malaria J., 15, 2016, 206.
98. 98 Manary, M.J., et al. Identification of pathogen genomic variants through an integrated pipeline. BMC Bioinform., 15, 2014, 63.
99. 99 Sepulveda, N., et al. A Poisson hierarchical modelling approach to detecting copy number variation in sequence coverage data. BMC Genom., 14, 2013, 128.
100. 100 Lukens, A.K., et al. Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 799–804.
101. 101 Ross, L.S., et al. In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth. J. Biol. Chem. 289 (2014), 17980–17995.
102. 102 Daniels, R.F., et al. Modeling malaria genomics reveals transmission decline and rebound in Senegal. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 7067–7072.
103. 103 Borrmann, S., et al. Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya. Sci. Rep., 3, 2013, 3318.
104. 104 Sidhu, A.B., et al. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298 (2002), 210–213.
105. 105 Gabryszewski, S.J., et al. Combinatorial genetic modeling of pfcrt-mediated drug resistance evolution in Plasmodium falciparum. Mol. Biol. Evol. 33 (2016), 1554–1570.
106. 106 Raj, D.K., et al. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J. Biol. Chem. 284 (2009), 7687–7696.
107. 107 Mu, J., et al. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol. Microbiol. 49 (2003), 977–989.
108. 108 Veiga, M.I., et al. Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat. Commun., 7, 2016, 11553.
109. 109 Hayward, R., et al. pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum. Mol. Microbiol. 55 (2005), 1285–1295.
110. 110 Frosch, A.E., et al. Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. J. Infect. Dis. 210 (2014), 1110–1114.
111. 111 Wilson, C.M., et al. Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol. Biochem. Parasitol. 57 (1993), 151–160.
112. 112 Duraisingh, M.T., et al. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol. Biochem. Parasitol. 108 (2000), 13–23.
113. 113 Price, R.N., et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364 (2004), 438–447.
114. 114 Duraisingh, M.T., et al. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol. Microbiol. 36 (2000), 955–961.
115. 115 Sidhu, A.B., et al. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol. Microbiol. 57 (2005), 913–926.
116. 116 Henry, M., et al. Plasmodium falciparum Na + /H + exchanger 1 transporter is involved in reduced susceptibility to quinine. Antimicrob. Agents Chemother. 53 (2009), 1926–1930.
117. 117 Okombo, J., et al. In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya. Antimicrob. Agents Chemother. 54 (2010), 3302–3307.
118. 118 Nkrumah, L.J., et al. Probing the multifactorial basis of Plasmodium falciparum quinine resistance: evidence for a strain-specific contribution of the sodium-proton exchanger PfNHE. Mol. Biochem. Parasitol. 165 (2009), 122–131.
119. 119 Menard, D., et al. Global analysis of Plasmodium falciparum Na(+)/H(+) exchanger (pfnhe-1) allele polymorphism and its usefulness as a marker of in vitro resistance to quinine. Int. J. Parasitol. Drugs Drug Resist. 3 (2013), 8–19.
120. 120 Pelleau, S., et al. Differential association of Plasmodium falciparum Na + /H + exchanger polymorphism and quinine responses in field- and culture-adapted isolates of Plasmodium falciparum. Antimicrob. Agents Chemother. 55 (2011), 5834–5841.
121. 121 Baird, J.K., Hoffman, S.L., Primaquine therapy for malaria. Clin. Infect. Dis. 39 (2004), 1336–1345.
122. 122 Cowman, A.F., et al. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 85 (1988), 9109–9113.
123. 123 Sirawaraporn, W., et al. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 1124–1129.
124. 124 Triglia, T., Cowman, A.F., Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 7149–7153.
125. 125 Brooks, D.R., et al. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 224 (1994), 397–405.
126. 126 Triglia, T., et al. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J. 17 (1998), 3807–3815.
127. 127 Mbengue, A., et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 520 (2015), 683–687.
128. 128 Srivastava, I.K., et al. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol. Microbiol. 33 (1999), 704–711.
129. 129 Berry, A., et al. Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. Trans. R. Soc. Trop. Med. Hyg. 100 (2006), 986–988.
130. 130 Musset, L., et al. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect. 8 (2006), 2599–2604.
131. 131 Pimentel, S., et al. Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda. Angola. Malaria J., 5, 2006, 30.
132. 132 Boggild, A.K., et al. Failure of atovaquone-proguanil malaria chemoprophylaxis in a traveler to Ghana. Travel. Med. Infect. Dis. 13 (2015), 89–93.
133. 133 Plucinski, M.M., et al. Novel mutation in cytochrome B of Plasmodium falciparum in one of two atovaquone-proguanil treatment failures in travelers returning from same site in Nigeria. Open Forum Infect. Dis., 1, 2014, ofu059.
134. 134 Talundzic, E., et al. Advanced molecular detection of malarone resistance. Antimicrob. Agents Chemother. 60 (2016), 3821–3823.
135. 135 Goodman, C.D., et al. Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes. Science 352 (2016), 349–353.